Pfizer Licenses Chai Discovery AI for Drug Research

Biopharmaceutical giant Pfizer has entered into a licensing agreement with Chai Discovery to integrate its generative AI platform into drug discovery processes ^[1]. This partnership provides Pfizer with early access to the advanced Chai-3 model ^[1][2]. The technology allows researchers to predict and reprogram molecular interactions to design new biomolecules from scratch ^[1].

The collaboration aims to significantly shorten drug development timelines ^[1][2]. By leveraging these AI capabilities, the companies seek to enhance the efficiency of the drug discovery engine ^[2][3]. Details of the agreement focus on accelerating research through high-fidelity molecular simulations provided by the platform ^[1][3].